GB201215357D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201215357D0
GB201215357D0 GBGB1215357.3A GB201215357A GB201215357D0 GB 201215357 D0 GB201215357 D0 GB 201215357D0 GB 201215357 A GB201215357 A GB 201215357A GB 201215357 D0 GB201215357 D0 GB 201215357D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1215357.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respivert Ltd
TopiVert Pharma Ltd
Original Assignee
Respivert Ltd
TopiVert Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd, TopiVert Pharma Ltd filed Critical Respivert Ltd
Priority to GBGB1215357.3A priority Critical patent/GB201215357D0/en
Publication of GB201215357D0 publication Critical patent/GB201215357D0/en
Application status is Ceased legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
GBGB1215357.3A 2012-08-29 2012-08-29 Compounds Ceased GB201215357D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB1215357.3A GB201215357D0 (en) 2012-08-29 2012-08-29 Compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1215357.3A GB201215357D0 (en) 2012-08-29 2012-08-29 Compounds
PCT/GB2013/052252 WO2014033448A1 (en) 2012-08-29 2013-08-28 Pyrazole derivatives as p38 map inhibitors
EP13759279.6A EP2890693A1 (en) 2012-08-29 2013-08-28 Pyrazole derivatives as p38 map inhibitors
US14/424,361 US9249125B2 (en) 2012-08-29 2013-08-28 Pyrazole derivatives as p38 MAP inhibitors

Publications (1)

Publication Number Publication Date
GB201215357D0 true GB201215357D0 (en) 2012-10-10

Family

ID=47045551

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1215357.3A Ceased GB201215357D0 (en) 2012-08-29 2012-08-29 Compounds

Country Status (4)

Country Link
US (1) US9249125B2 (en)
EP (1) EP2890693A1 (en)
GB (1) GB201215357D0 (en)
WO (1) WO2014033448A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010006739A (en) 2007-12-19 2010-10-08 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use.
NZ601085A (en) 2010-02-01 2015-04-24 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2013050757A1 (en) 2011-10-03 2013-04-11 Respivert Limited 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
WO2014076484A1 (en) 2012-11-16 2014-05-22 Respivert Limited Kinase inhibitors
WO2014140582A1 (en) 2013-03-14 2014-09-18 Respivert Limited Kinase inhibitors
WO2014162121A1 (en) 2013-04-02 2014-10-09 Topivert Pharma Limited Kinase inhibitors based upon n-alkyl pyrazoles
KR20150138855A (en) 2013-04-02 2015-12-10 레스피버트 리미티드 Urea derivatives useful as kinase inhibitors
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
US9890185B2 (en) 2013-12-20 2018-02-13 Respivert Limited Urea derivatives useful as kinase inhibitors
EP3357919B1 (en) 2014-02-14 2019-11-20 Respivert Limited Aromatic heterocyclic compounds as antiinflammatory compounds
WO2016051187A1 (en) 2014-10-01 2016-04-07 Respivert Limited Diaryl urea derivatives as p38 kinase inhibitors
BR112018067552A2 (en) 2016-04-06 2019-01-08 Topivert Pharma Ltd kinase inhibitors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
JP2001526222A (en) 1997-12-22 2001-12-18 バイエル コーポレイション Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
AT328873T (en) 1997-12-22 2006-06-15 Bayer Pharmaceuticals Corp Inhibition of raf-kinase using aryl and heteroaryl substituted heterocyclic urea
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
AT549328T (en) 1999-01-19 2012-03-15 Boehringer Ingelheim Pharma Aromatic-heterocyclic compounds as anti-inflammatory agents
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
ES2253233T3 (en) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedure for synthesis of urea heteroaril substituted compounds.
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
DE60036726T2 (en) 1999-11-16 2008-02-07 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Urea derivatives as anti-inflammatory agents
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
JP2004536845A (en) 2001-07-11 2004-12-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Methods for treating cytokine-mediated diseases
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
EP1480973B1 (en) 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
MXPA06012394A (en) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Substituted pyrazolyl urea derivatives useful in the treatment of cancer.
GB0500435D0 (en) 2005-01-10 2005-02-16 Novartis Ag Organic compounds
MY159230A (en) 2008-10-02 2016-12-30 Respivert Ltd P38 map kinase inhibitors
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
EP2370428B1 (en) * 2008-12-11 2016-08-10 Respivert Limited P38 map kinase inhibitors
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
GB0921730D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Method of treatment
GB0921731D0 (en) 2009-12-11 2010-01-27 Respivert Ltd Theraputic uses
CN103804295B (en) 2010-03-15 2016-11-23 宇部兴产株式会社 The method preparing amide compound
GB201005589D0 (en) 2010-04-01 2010-05-19 Respivert Ltd Novel compounds
WO2011124930A1 (en) * 2010-04-08 2011-10-13 Respivert Limited P38 map kinase inhibitors
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
GB201010196D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Methods
JP5973426B2 (en) 2010-06-17 2016-08-23 レスピバート・リミテツド Respiratory preparation containing P38 MAPK inhibitor
GB201010193D0 (en) * 2010-06-17 2010-07-21 Respivert Ltd Medicinal use
WO2013050757A1 (en) 2011-10-03 2013-04-11 Respivert Limited 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
US20150225373A1 (en) 2012-08-29 2015-08-13 Respivert Limited Kinase inhibitors
WO2014033446A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors
WO2014033449A1 (en) 2012-08-29 2014-03-06 Respivert Limited Kinase inhibitors

Also Published As

Publication number Publication date
US9249125B2 (en) 2016-02-02
EP2890693A1 (en) 2015-07-08
WO2014033448A1 (en) 2014-03-06
US20150203475A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
PT2807164T (en) Imidazopyrrolidinone compounds
GB201304182D0 (en) No details
EP2842955A4 (en) Trk-INHIBITING COMPOUND
ZA201503689B (en) Zinc-lysine complex
EP2925129A4 (en) Pro-neurogenic compounds
SG11201406274VA (en) Novel compounds
HK1215183A1 (en) Protein-polymer-drug conjugates --
GB201214750D0 (en) Compounds
IL268013D0 (en) Tetrahydropyrazolopyrimidine compounds
HK1208025A1 (en) Aminoimidazopyridazines
IL253775D0 (en) נוגדנים בעלי שרשרת קלה מהונדסת היסטידין ובעלי חיים לא אנושיים שעברו שינוי גנטי להכנתם
GB201215357D0 (en) Compounds
EP2754580A4 (en) Dumptruck
GB201209138D0 (en) Compounds
GB201207406D0 (en) Novel compounds
EP2922550A4 (en) Novel compounds
EP2934531A4 (en) Combination
GB201403961D0 (en) No details
HK1200830A1 (en) Substituted pyrrolidine-2-carboxamides -2-
GB201212871D0 (en) Novel compounds
SI2922549T1 (en) Novel compounds
EP2887803A4 (en) Pro-neurogenic compounds
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
EP2922547A4 (en) Novel compounds
ZA201504331B (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)